CRISPR Therapeutics AG (CRSP)
| Market Cap | 5.75B +16.8% |
| Revenue (ttm) | 13.39M -64.8% |
| Net Income | -451.14M |
| EPS | -4.76 |
| Shares Out | 96.69M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,448,426 |
| Open | 59.72 |
| Previous Close | 58.12 |
| Day's Range | 58.89 - 62.54 |
| 52-Week Range | 44.12 - 78.48 |
| Beta | 1.74 |
| Analysts | Buy |
| Price Target | 87.56 (+47.16%) |
| Earnings Date | Aug 3, 2026 |
About CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as deve... [Read more]
Financial Performance
In 2025, CRISPR Therapeutics AG's revenue was $3.51 million, a decrease of -90.59% compared to the previous year's $37.31 million. Losses were -$581.60 million, 58.8% more than in 2024.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price target is $87.56, which is an increase of 47.16% from the latest price.
News
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026.
CRISPR Therapeutics AG Earnings release: Q2 2026
CRISPR Therapeutics AG released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
CRISPR Therapeutics AG Quarterly report: Q2 2026
CRISPR Therapeutics AG has published its Q2 2026 quarterly earnings report on August 3, 2026.
CRISPR Therapeutics (CRSP) Price Forecast: Dual Breakout Targets Higher Prices
CRISPR Therapeutics confirmed a dual breakout from inverse head and shoulders patterns, strengthening the bullish outlook and pointing to additional upside if resistance continues to give way.
3 Companies Redefining Healthcare Innovation
The Healthcare Technology and Innovation index (HTEC) was launched back in 2019 with a specific purpose in mind: to allow investors to participate in the evolution of healthcare needed to address crit...
CRISPR Therapeutics AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is prioritizing cardiovascular and autoimmune programs, with five clinical trial readouts expected in the second half of the year. Key assets include CTX611, CTX310, and allogeneic CD19 zugo-cel, with pivotal trials planned for 2027 and a strong financial position supporting independent or partnered advancement.
CRISPR Therapeutics AG Transcript: 46th Annual William Blair Growth Stock Conference
The company is rapidly expanding its gene editing and siRNA pipeline, with CASGEVY's global launch progressing and multiple clinical readouts expected by late 2026. Strategic partnerships and innovation in conditioning regimens and delivery platforms position it for leadership in biotech.
CRISPR Therapeutics AG Transcript: Jefferies Global Healthcare Conference 2026
A broad pipeline is advancing with multiple late-stage assets, including CTX310, zugo-cel, and CTX611, all expected to reach key clinical milestones by year-end. CASGEVY commercialization is accelerating, and several new programs are poised for significant data readouts in the next 12 months.
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
ZUG, Switzerland and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team are scheduled to participate in the followin...
CRISPR Therapeutics AG Transcript: Bank of America Global Healthcare Conference 2026
Six key programs will have major data readouts in the next 12–18 months, with CASGEVY showing exponential patient initiation and expanding global access. Pipeline assets in cardiovascular, autoimmune, and rare diseases are advancing, with gene editing and siRNA approaches positioned for broad impact.
CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference
ZUG, Switzerland and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Bank of America Securiti...
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026.
CRISPR Therapeutics AG Earnings release: Q1 2026
CRISPR Therapeutics AG released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
CRISPR Therapeutics AG Quarterly report: Q1 2026
CRISPR Therapeutics AG has published its Q1 2026 quarterly earnings report on May 4, 2026.
CRISPR Therapeutics AG Proxy statement: Proxy filing
CRISPR Therapeutics AG filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
CRISPR Therapeutics AG Proxy statement: Proxy filing
CRISPR Therapeutics AG filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
CRISPR Therapeutics AG Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is rapidly expanding its pipeline beyond Casgevy, with six programs set for near-term data and a focus on cardiovascular, autoimmune, and oncology franchises. Innovations in gene editing, delivery, and siRNA are driving new therapies, while strong financials support broad R&D investment.
Wall Street Is Completely Wrong About These 5 Stocks
Steven Orr, Founder & CEO, Quasar Markets breaks down the five stocks Wall Street is mispricing and explains how he's finding real opportunities across AI, biotech, crypto and consumer right now.
CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
ZUG, Switzerland and BOSTON, April 07, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the 25th Annual Needham Vi...
CRISPR Therapeutics AG Proxy statement: Proxy filing
CRISPR Therapeutics AG filed a proxy statement on April 2, 2026, providing details for shareholder voting and corporate governance matters.
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
ZUG, Switzerland and BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its conv...
CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering
ZUG, Switzerland and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced its intention to offer, subject to market conditions and other fac...
CRISPR Therapeutics AG Transcript: TD Cowen 46th Annual Health Care Conference
The session highlighted a strategic shift toward disease-focused franchises in cardiovascular and autoimmune areas, with robust pipeline progress expected by 2027. Casgevy momentum continues, while in vivo, siRNA, and cell therapy programs advance, supported by strong early data and upcoming clinical milestones.
CRISPR Therapeutics AG Transcript: Citi’s 2026 Virtual Oncology Leadership Summit
Zugo-cel, an allogeneic CAR-T with advanced edits, is advancing in both oncology and autoimmune indications, showing strong early efficacy and broad applicability. Regulatory and commercialization strategies focus on parallel development, competitive pricing, and global access, while in vivo CAR-T platforms are being engineered for future expansion.